Mainland China

HKTDC twin jewellery shows attract exhibitors and buyers from 130 countries and regions, delivering robust results

Retrieved on: 
Sunday, March 5, 2023
Diamond, Gems, Hong Kong Trade Development Council, Social media, Relaxation, Hong Kong International Lighting Fair, Travel, GBA, Hong Kong Trade Development Council Trade Fairs, Hong Kong Electronics Fair, Growth, Heel, Jewellery, HKTDC, Policy, Jaipur Jewellery Show, ASEAN, Film industry, Online shopping, Gemstone, Mainland China

Organised by the Hong Kong Trade Development Council (HKTDC), the 39th HKTDC Hong Kong International Jewellery Show and the 9th HKTDC Hong Kong International Diamond, Gem & Pearl Show gathered over 2,500 exhibitors and successfully concluded today.

Key Points: 
  • Organised by the Hong Kong Trade Development Council (HKTDC), the 39th HKTDC Hong Kong International Jewellery Show and the 9th HKTDC Hong Kong International Diamond, Gem & Pearl Show gathered over 2,500 exhibitors and successfully concluded today.
  • Organised by the Hong Kong Trade Development Council (HKTDC), the 39th HKTDC Hong Kong International Jewellery Show and 9th HKTDC Hong Kong International Diamond, Gem & Pearl Show concluded successfully.
  • Sophia Chong, Deputy Executive Director of the HKTDC, said: "We are delighted to see the overwhelming support from industry buyers and exhibitors for the twin shows.
  • In addition to the high volume of buyers and exhibitors, robust business results were seen across the shows.

Bilibili Inc. Announces Inclusion of Its Class Z Ordinary Shares in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect Programs

Retrieved on: 
Friday, March 10, 2023
Shanghai Stock Exchange, HKEX, Shenzhen Stock Exchange, Stock exchange, Mainland China, Shenzhen-Hong Kong Stock Connect, Film industry, Security (finance)

SHANGHAI, China, March 10, 2023 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that the Company’s Class Z ordinary shares traded on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) have been included in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect programs, both effective March 13, 2023.

Key Points: 
  • SHANGHAI, China, March 10, 2023 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that the Company’s Class Z ordinary shares traded on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) have been included in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect programs, both effective March 13, 2023.
  • Following its inclusion, eligible investors in the Chinese Mainland will have direct access to the trading of Bilibili’s Class Z ordinary shares.
  • The inclusion of Bilibili’s Class Z ordinary shares in the programs was pursuant to the Announcement on Adjustment of the Stock List of the Shenzhen-Hong Kong Stock Connect issued by the Shenzhen Stock Exchange and the Announcement on Adjustment of the Stock List of the Shanghai-Hong Kong Stock Connect issued by the Shanghai Stock Exchange.

Kingworld Medicines Earns "Shenzhen Time-honored Brand" Title Again

Retrieved on: 
Tuesday, February 28, 2023
Nin Jiom Pei Pa Koa, Mosquito, Pain, Mainland China, Chronic pain, Athlete, Arthritis, Friends, Bruise, WeChat, COVID-19, Dietary supplement, King World Productions, Lacticaseibacillus rhamnosus

As an industry leader of more than two decades, Kingworld Medicines has won market acclaims and was again named a "Shenzhen Time-honored Brand".

Key Points: 
  • As an industry leader of more than two decades, Kingworld Medicines has won market acclaims and was again named a "Shenzhen Time-honored Brand".
  • The Company's own medicine brand Kingworld Imada Red Flower Oil recently made the official topical oil at the Shenzhen Bao'an Marathon.
  • The topical oil is among the best of Kingworld's own brand medicines, known for improving circulation, fending off coldness and reducing swelling and pain.
  • Kingworld Medicines will send teams to take part in the event.

Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Retrieved on: 
Monday, February 27, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, US, Safety, HKEX, IND, Research, SSE, Medication, NMPA, Chinese, Pharmaceutical industry, Vaccine, Mainland China

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
  • Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China.
  • “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen.
  • Chipscreen NewWay will rapidly advance the clinical stage research and development of YH008.”

Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008

Retrieved on: 
Monday, February 27, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, US, Safety, HKEX, IND, SSE, Medication, NMPA, Chinese, Pharmaceutical industry, Vaccine, Mainland China

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co., Ltd. (“Eucure Biopharma”), has reached an exclusive licensing agreement with Chipscreen NewWay Biosciences (“Chipscreen NewWay”), a holding subsidiary of Shenzhen Chipscreen Biosciences Co., Ltd. (“Chipscreen Biosciences”, SSE: 688321) for the clinical development and commercialization of bispecific antibody YH008 in Greater China (including Mainland China, Hong Kong, Macau and Taiwan).
  • Eucure Biopharma retains YH008’s global rights to develop and commercialize YH008 outside Greater China.
  • “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen.
  • Chipscreen NewWay will rapidly advance the clinical stage research and development of YH008.”

Clarivate and KAIST Innovation Strategy and Policy Institute Release Report on the Global AI Chip Innovation Landscape

Retrieved on: 
Wednesday, February 22, 2023
Organization, Processor (computing), Memory, CLVT, United Kingdom, University, NYSE, Graphics processing unit, Artificial intelligence, Ecosystem, Research, Derwent World Patents Index, Intelligence, ISPI, Neuromorphic engineering, Policy, R, Cryptocurrency, Medical device, Clarivate, Mainland China, AI

LONDON, Feb. 22, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform the world, and the KAIST Innovation Strategy and Policy Institute (ISPI), a top research institution in South Korea today launched a collaborative report on the global innovation landscape of the artificial intelligence (AI) chip industry. The report suggests it is crucial to build an innovation ecosystem to stimulate mutual-cooperation among universities, enterprises and government-funded research institutes.

Key Points: 
  • Currently, Mainland China and the United States account for about 80 percent of the global patents in the field of AI chip innovation.
  • "This report analyzes the competitive landscape of AI chip technology and provides key insights and directions for developing innovation strategies for the development of AI chips.
  • Therefore, the competition for the R&D of AI chip technology is intensifying," said Professor Wonjoon Kim, Director, KAIST Innovation Strategy and Policy Institute.
  • "The report guides us to the future of the global AI chip industry, a sector full of changes and potential.

Clarivate and KAIST Innovation Strategy and Policy Institute Release Report on the Global AI Chip Innovation Landscape

Retrieved on: 
Wednesday, February 22, 2023
Organization, Processor (computing), Memory, CLVT, United Kingdom, University, NYSE, Graphics processing unit, Artificial intelligence, Ecosystem, Research, Derwent World Patents Index, Intelligence, ISPI, Neuromorphic engineering, Policy, R, Cryptocurrency, Medical device, Clarivate, Mainland China, AI

LONDON, Feb. 22, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform the world, and the KAIST Innovation Strategy and Policy Institute (ISPI), a top research institution in South Korea today launched a collaborative report on the global innovation landscape of the artificial intelligence (AI) chip industry. The report suggests it is crucial to build an innovation ecosystem to stimulate mutual-cooperation among universities, enterprises and government-funded research institutes.

Key Points: 
  • Currently, Mainland China and the United States account for about 80 percent of the global patents in the field of AI chip innovation.
  • "This report analyzes the competitive landscape of AI chip technology and provides key insights and directions for developing innovation strategies for the development of AI chips.
  • Therefore, the competition for the R&D of AI chip technology is intensifying," said Professor Wonjoon Kim, Director, KAIST Innovation Strategy and Policy Institute.
  • "The report guides us to the future of the global AI chip industry, a sector full of changes and potential.

Fosun International's 2021 Annual Report Wins Gold Award at the 2022 International ARC Awards

Retrieved on: 
Friday, January 27, 2023
The Spring Festival, Club Med, Letter, Hospital, Airport authority, Gold Award, Face, Ali Baba, Mainland China, Future, Hang Seng Bank, Commercial bank, NWS Holdings, Gold, China Construction Bank, New Year, CK Hutchison Holdings, Weather, Citigroup, Tablet, Happiness, Pharmaceutical industry in China, Fruit, CLP Group, Investment, HKEX, Photography, Morgan Stanley, Goldman Sachs, New World Development, Spring Festival, International, Annual report, Government, Imperial Bank of China, Accumulation, COVID-19, ARC, The Company, Organization, Vaccination, Film industry, Pharmaceutical industry, Fosun International, China Telecom, Nomura, Silver, Health, Azvudine

The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022 International ARC Awards.

Key Points: 
  • The 2021 annual report of Fosun International Limited ("Fosun International" or the "Company", HKEX: 00656) won Gold Award in the "Traditional Annual Report" category of the 2022 International ARC Awards.
  • Hailed as the "Academy Awards of annual reports", the International ARC Awards is the world's most prestigious competition honoring excellence in annual reports.
  • In addition to Fosun International, CK Hutchison Holdings and NWS Holdings also won awards in the Traditional Annual Report - Diversified Business category of the 2022 International ARC Awards.
  • Hailed as the "Academy Awards of annual reports", the International ARC Awards is globally recognized for its openness and fairness, providing a platform for the highest standards in the annual report industry.

Fosun International Wins Platinum Award at The Asset ESG Corporate Awards 2022

Retrieved on: 
Thursday, January 26, 2023
Benchmark, The Spring Festival, Asset, Club Med, ABC Family Worldwide, Conference, Policy, Gold Award, Face, Gold Award (Girl Scouts of the USA), Mainland China, Pfizer–BioNTech COVID-19 vaccine, Hang Seng Composite Index Series, Investment, New Year, Weather, Citigroup, Central Economic Work Conference, ESG, Newsfirst Platinum Awards, Omicron, Anworth Mortgage Asset Corporation, Communication, Bank, Happiness, Agricultural Bank, Fruit, MSCI, S&P Global Ratings, HKEX, Platinum, Bank of China, Morgan Stanley, Goldman Sachs, Hang Seng China 50 Index, Spring Festival, Tourism, COVID-19, Statistics, Hang Seng Index, Vaccination, Cryptocurrency, Security (finance), Fosun International, Nomura, Wealth, Health, Azvudine

HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed by The Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2022.

Key Points: 
  • HONG KONG, Jan. 26, 2023 /PRNewswire/ -- Fosun International Limited ("Fosun International" or the "Company") (HKEX: 00656) was informed by The Asset, the renowned international asset management and investment magazine, that Fosun has garnered the Platinum Award at The Asset ESG Corporate Awards 2022.
  • This year, Fosun International was accredited with the Platinum Award by The Asset for the first time after being presented with the Gold Award for four consecutive years.
  • Organized by The Asset, a renowned Asian financial magazine, The Asset Corporate Awards that has been running for many years is one of the world's leading environmental, social and governance (ESG) awards.
  • This year, Fosun International was accredited with the Platinum Award at The Asset ESG Corporate Awards 2022, reflecting the magazine's recognition of Fosun's outstanding performance in various fields including financial performance, management, corporate governance, social and environmental responsibility, investor relations, information disclosure and corporate communication.

Autograph Tower at Thamrin Nine Complex Receives Award from PropertyGuru Asia Property Awards Grand Final

Retrieved on: 
Friday, January 20, 2023
Cloud, Knowledge, Grand final, Flow (real estate company), Astoria, Partnership, MRT, Nigerian Institution of Estate Surveyors and Valuers, LRT, HLB, Glass, Skybox, Sky Box Office, IWG, Waldorf Astoria New York, Orientation, RISM, Grand, Rail profile, Airport, Thamrin Nine, 2009 NRL Grand Final, Kohler, John Young (building contractor), The Digital Hub, NYSE, KPF, History of the world's tallest buildings, JLL, Sunlight, Sky garden, Telephone numbers in Hungary, Heart, Bell tower, Country, Dato, Transit-oriented development, Film industry, Hotel, Mainland China

Also known as the finale of the 2022 PropertyGuru Asia Property Awards series, the Grand Final was presented in 48 categories at The Athenee Hotel, a Luxury Collection Hotel, Bangkok.

Key Points: 
  • Also known as the finale of the 2022 PropertyGuru Asia Property Awards series, the Grand Final was presented in 48 categories at The Athenee Hotel, a Luxury Collection Hotel, Bangkok.
  • The award-winning companies and projects shortlisted as nominees to the Grand Final competed for 9 Developer titles; 24 Development titles; and 14 Design titles.
  • Indonesia was represented with six regional wins including Autograph Tower at Thamrin Nine Complex as Best Office Development (Asia).
  • After winning in a national level (Indonesia Property Award) as Best Highrise Development, Autograph Tower at Thamrin Nine Complex was recognized as Best Office Development (Asia).